AI Life Sciences Real Estate

The Problem

Your property valuations and deal screening can’t keep up with fast-moving life sciences markets

Organizations face these key challenges:

1

Analysts spend days assembling comps, lease terms, and facility specs across disconnected sources

2

Valuations vary by appraiser/market and are hard to audit or reproduce for IC and lenders

3

High-potential deals are missed because screening is manual and alerts come too late

4

Forecasts are updated infrequently, so pricing and risk assumptions drift from reality

Impact When Solved

Faster underwriting and investment decisionsMore consistent, auditable valuationsScale market coverage without adding headcount

The Shift

Before AI~85% Manual

Human Does

  • Manually gather comps from brokers/MLS and reconcile discrepancies
  • Interpret facility fit (lab readiness, power/HVAC, cleanroom potential) from notes and site visits
  • Build/update spreadsheet valuation models and write memos for IC
  • Manually scan markets for opportunities and track watchlists

Automation

  • Basic alerts from listing platforms and keyword searches
  • Static dashboards/BI reports with limited feature engineering
With AI~75% Automated

Human Does

  • Define underwriting rules, risk tolerances, and approve model governance
  • Validate AI outputs on edge cases (unique assets, thin comp markets) and perform final investment approval
  • Conduct targeted site visits and negotiate terms using AI-generated comps and scenarios

AI Handles

  • Continuously ingest/clean sales, listings, lease data, zoning/permitting, and facility attributes
  • Generate automated valuations with confidence bands and comparable selection rationales
  • Run market forecasting and scenario analysis (rent growth, cap rates, vacancy, conversion costs)
  • Screen and rank opportunities, push alerts on mispricing, trend shifts, and new matching listings

Real-World Use Cases

Free access to this report